(News Bulletin 247) – 3M announced Thursday that it plans to invest more than 137 million euros in the development of biopharmaceutical filtration technologies in Europe, a rapidly growing market.
The American industrial conglomerate specifies that this envelope will make it possible to finance the improvement of installations and equipment as well as the creation of 60 full-time positions in its European manufacturing plants.
This new investment aims in particular to accelerate the development of filtration equipment designed for bioprocessing applications and the manufacture of biological pharmaceutical products.
Thanks to these small molecules, pharmaceutical laboratories will be able to develop innovative therapies in the treatment of diseases such as rheumatoid arthritis, multiple sclerosis and certain cancers.
The group points out that filtration and purification play essential roles in the manufacture of biopharmaceutical drugs by capturing impurities while allowing necessary drug substances to pass through.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
